Law Project for
Note: This Page is Substantially Out of Date
Symbyax (Zyprexa and
Prozac combination) Patient Information Sheet that will probably be watered
down or even eliminated.
Stimulants and ADHD: FDA March, 2006 Hearings
Dear Health Care
Professional" Alert on Haldol, September 17, 2007. Information for
Healthcare Professionals Haloperidol (marketed as Haldol, Haldol Decanoate and
Haldol Lactate) FDA ALERT [9/2007]: This Alert highlights revisions to the
labeling for haloperidol (marketed as Haldol, Haldol Decanoate and Haldol
Lactate). The updated labeling includes WARNINGS stating that Torsades de
Pointes and QT prolongation have been observed in patients receiving
haloperidol, especially when the drug is administered intravenously or in higher
doses than recommended. Haloperidol is not approved for intravenous use
FDA June 18, 2007,
Recommendation of Approvable Action for risperidone (Risperdal®) for the
Treatment of Schizophrenia and Bipolar I Disorder in Pediatric Patients
(response to PWR).
FDA Issues Warning Letter to Cephalon regarding
false and misleading promotion of Provigil (modanfil), February 27, 2007..
Making Sense of Coming off Psychiatric Drugs from Mind in the UK.
January 20, 2007,
study on the spermicidal and anti-STI
properties of antidepressants. In vitro tests found that all of the
SSRIs are spermicidal, and four types also kill the bacteria that cause
Trichomonas, the world's most common sexually transmitted disease.
November 16, 2006, FDA Warning
Letter to Astra-Zeneca for misleading Seroquel (quetiapine) marketing materials
for minimizing the risk of hyperglycemia and diabetes mellitus and failing to
communicate important information regarding neuroleptic malignant syndrome,
tardive dyskinesia and the bolded cataracts precaution.
SSRI Antidepressants and
August 4, 2006, "Dear Health Care
Professional" letter from GlaxoSmithKline warning of a host of problems created
by Dexedrine, including heart attacks and psychotic reactions. GSK
promotes Dexedrine for use by kids diagnosed with "Attention Deficit
BBC July 1, 2006, article on Clozapine,
Schizophrenia drug 'health risk'.
Health Canada "Dear Health Care Letter" regarding the heart damaging
characteristics of ADHD drugs, May 2006.
Associated Press, February 10, 2006:
FDA Panel recommends "Black Box"
warning regarding lethal potential of ADHD Drugs (Ritalin, etc.).
Anatomy of an Epidemic:
Psychiatric Drugs and the Astonishing Rise of Mental Illness in America, by
Robert Whitaker, Ethical Human Psychology and Psychiatry, Volume 7,
Number I: 23-35 Spring 2005.
Cytogenetic effects in children treated
with methylphenidate, by Randa A. El-Zeina, Sherif Z. Abdel-Rahmanb, Matthew
J. Hay, Mirtha S. Lopez, Melissa L. Bondy, Debra L. Morris, Marvin S. Legator in
Cancer Letters 2 xx (2005) 1–8, documenting a 3, 4.3 and 2.4-fold
increase in chromosome aberrations, sister chromatid exchanges and micronuclei
frequencies in the pediatric use of Ritalin.
June 1, 2005, Freedom of
Information Act transmittal of Adverse Reactions to Olanzapine (Zyprexa).
FDA Issues Public Health
Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in
Elderly Patients, April 11, 2005.
Dr. Grace Jackson's June 6,
2004 Public Lecture, "What Doctors May Not Tell You About Psychiatric
Drugs," to the UCE Centre for Community Mental Health, in Birmingham,
Pfizer's August, 2004, "Dear Health Care
Practitioner" letter on Geodon and increased risk of diabetes and related
GlaxoSmithKline Settles NY Fraud Suit, August 26, 2004. See,
Consent Decree (Settlement)
21, 2004 "Dear Health Care Provider" Letter for Risperidone (Risperdal)
warning about the risk of diabetes.
- April 19, 2004, FDA
Warning Letter to Janssen about its previous Dear Health Care Provider
being "false or misleading," which resulted in the July 21, 2004 letter.
- Astra Zeneca April
22, 2004, "Dear Health Care Provider" updated letter on Serequel after the
FDA said its earlier letter was improper.
Squibb March 25, 2004, Myers "Dear Dr. Health Care Practitioner" letter
for Abilify (aripiprazole).
- Eli Lilly March 1, 2004, "Dear
Health Care Provider Letter" for Olanzapine (Zyprexa) warning about the
risk of diabetes.
- Benzodiazepines: How They Work and
How to Withdraw by Professor C H Ashton DM, FRCP
- Sen. Grassley's March 25, 2004,
Letter to FDA opening investigation on SSRI anti-depressants.
- Allen Jones' Full
Whistle-Blower Report on Drug Company influence on states' drug purchases.
Update from the Baum Hedland law firm.
Adverse Drug Effect Websites
Off Label Prescribing Stories about Prozac leading
to Milton Cole's Death
ASPIRE's Research Compendium
focused on SSRIs (Paxil, Prozac, Zoloft, etc.)
Drug Company's Promotion
of Unauthorized Use of Neurontin Exposed. New York Times
Drug giant accused of false claims (for Neurontin): Whistleblower alleges
illegal encouragement of off-label use MSNBC
paroxetine (Paxil) can be severe, warns FDA
Neuroleptics and Chronic Mental Illness.
Alprazolam-Induced Panic Disorder
Researchers in the UK find
alarmingly high mortality with the SSRI anti-depressants (Prozac, Paxi., etc).
Research reviewed by Robert
Whitaker since the Release of Mad in America.
from a Mad World
Commonly-Prescribed Antidepressants Are Extremely Dangerous for Some
Warning About Antipsychotic Drug (Zyprexa)
Grand Jury Investigation
Demanded against Eli Lilly for fraudulently concealing dangerousness of Prozac.
Researchers warn antipsychotic drug might be linked to diabetes
Revised safety labeling for
Psychiatric Risk Management–Accutane
2002 Safety Alert -
Zoloft (sertraline hydrochloride)
Glaxo Smith Kline internal confidential memo (1998) stating it is the company's
policy to conceal evidence from regulators.
ClinicalTrials.Gov is a database of
The FDA has a reporting system which the public and physicians are encouraged to
FAIR USE NOTICE: These links may contain copyrighted (© ) material the use of
which has not always been specifically authorized by the copyright owner. Such
material is made available to advance understanding of ecological, political,
human rights, economic, democracy, scientific, moral, ethical, and social
justice issues, etc. It is believed that this constitutes a 'fair use' of any
such copyrighted material as provided for in section 107 of the US Copyright
Law. In accordance with Title 17 U.S.C. Section 107, this material is used for
non-profit educational purposes. For more information go to:
http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use
copyrighted material for purposes of your own that go beyond 'fair use', you
must obtain permission from the copyright owner. Any copyright owner who
objects to the use of their copyrighted material should send an e-mail to
Last Modified 3/12/2010
Copyright © 2002-2010 Law Project For Psychiatric Rights All Rights Reserved